BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//jEvents 2.0 for Joomla//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:STANDARD
DTSTART:20251026T020000
RDATE:20260329T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:Europe/Berlin CET
END:STANDARD
BEGIN:STANDARD
DTSTART:20261025T020000
RDATE:20270328T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:Europe/Berlin CET
END:STANDARD
BEGIN:STANDARD
DTSTART:20271031T020000
RDATE:20280326T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:Europe/Berlin CET
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250922T080000
RDATE:20251026T020000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:Europe/Berlin CEST
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20260329T030000
RDATE:20261025T020000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:Europe/Berlin CEST
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20270328T030000
RDATE:20271031T020000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:Europe/Berlin CEST
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:13901819db5751ddc9f6c527b7f10a73
CATEGORIES:Kongresse
CREATED:20260824T103733
SUMMARY:5th Lipid Nanoparticles Development Summit Europe - Berlin
LOCATION:Dorint Kurfurstendamm Berlin
DESCRIPTION;ENCODING=QUOTED-PRINTABLE:\n\nThe 5th Lipid Nanoparticles Development Summit Europe, now free to atte
 nd, returns to Berlin at a pivotal moment for the field, as LNPs move beyon
 d COVID-19 vaccines into broader therapeutic applications, including gene e
 diting, oncology and in vivo cell therapy. This meeting brings together lea
 ding biotech, pharma and academic experts to tackle the biggest barriers pr
 eventing LNPs from reaching their full clinical potential.\n\n\nWhat sets t
 his event apart is its end-to-end focus, covering everything from early des
 ign and intracellular delivery, through analytical and CMC strategy, to reg
 ulatory alignment and scalable manufacturing. Unlike traditional meetings, 
 it goes beyond well-known challenges to spotlight next-generation innovatio
 ns, including extrahepatic targeting, hybrid nanoparticle systems and strat
 egies for repeat dosing and reduced toxicity.\n\n\nThe timing couldn't be m
 ore critical. As the industry faces increasing scrutiny around safety, deli
 very precision and commercial viability, there is a growing need to align i
 nnovation with real-world application and regulatory expectations. This sum
 mit provides a unique platform to do exactly that, through expert-led sessi
 ons, interactive debates and practical case studies.\n\n\nFor anyone seriou
 s about advancing LNP-based therapeutics, this is the forum to gain clarity
 , challenge assumptions and accelerate progress.\n\n\nURLs:\nWebsite: https
 ://go.evvnt.com/3625845-0?pid=1357\nTickets: https://go.evvnt.com/3625845-2
 ?pid=1357\nBrochure: https://go.evvnt.com/3625845-3?pid=1357\n\n\nDate and 
 Time: Wednesday, 23 September 2026 at 08:00 - Thursday, 24 September 2026 a
 t 16:15\n\n\nVenue details: Dorint Kurfurstendamm Berlin, 41 Augsburger Str
 aße, Berlin, Berlin, 10789, Germany\n\n\nCategory: Conferences | Science, H
 ealth and Medicine | Pharmaceuticals | Drug Development\n\n\nPrices:\nDrug 
 Developer Pricing - Conference Only (Free to Attend): EUR 0.00,\nAcademic a
 nd Small Biotech Pricing - Conference Only (Free to Attend): EUR 0.00,\nSol
 ution and Service Provider Pricing - Conference Only: EUR 3099.00\n\n\nSpea
 kers: Ansgar Santel, Chief Executive Officer, Pantherna Therapeutics, Suzan
 ne SaffieSiebert, Chief Executive Officer, SiSaf, Roy Pattipeiluhu, Directo
 r, Early-Stage Formulation Process Development, LNP Technology, BioNTech, P
 anagiota Papadopoulou, Marie Skłodowska-Curie Postdoctoral Fellow, National
  Hellenic Research Foundation, Heinrich Haas, Chief Technology Officer, Neo
 Vac, Chuan-En Lu, Senior Scientist, Process Analytical Technology, Global M
 edicines Development, AstraZeneca, Dan Shores, Partner, Rothwell Figgs, Ale
 xander Kros, Full Professor, Leiden University, Mengjie Shen, Scientist, Ab
 ogen Biosciences, Kamalinder Kaur Singh, Chair in Pharmaceutical Technology
  and Drug Delivery, School of Pharmacy and Biomedical Sciences, University 
 of Central Lancashire, Mahdi Zeraati, Cancer Institute Fellow, University o
 f Sydney, Pengbo Guo, Head of Product Development, CybernaX Biotechnologies
 , Shilpkala Gade, Higher Scientist, MHRA, Gholan Hamraz, PhD Candidate, Bio
 NTech, Janos Szebeni, Group Head at the Department of Translational Medicin
 e, Semmelweis University, Maria Irujo, Formulation and Pharmaceutical Innov
 ation, Advanced BioDesign\n
DTSTAMP:20260901T151521Z
DTSTART;TZID=Europe/Berlin:20260923T080000
DTEND;TZID=Europe/Berlin:20260924T161500
SEQUENCE:0
TRANSP:OPAQUE
END:VEVENT
END:VCALENDAR